# Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma

> **NCT07179900** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Hebei Medical University Fourth Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** QL1706
- **RADIATION:** Radiotherapy
- **DRUG:** Sintilimab
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT07179900
- **Lead sponsor:** Hebei Medical University Fourth Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12
- **Primary completion:** 2027-12
- **Final completion:** 2028-10
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07179900

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07179900, "Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-08-24 from https://api.ai-analytics.org/clinical/NCT07179900. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*